title: Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease.
authors.forename: Johannes
authors.initials: J
authors.lastname: Levin
authors.forename: Joachim
authors.initials: J
authors.lastname: Neudert
authors.forename: Ludwig
authors.initials: L
authors.lastname: Zwermann
authors.forename: Michael
authors.initials: M
authors.lastname: Näbauer
authors.forename: Kai
authors.initials: K
authors.lastname: Bötzel
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077465:Cabergoline; D018618:Echocardiography, Doppler, Color; D004873:Ergolines / Q000009:adverse effects* / Q000627:therapeutic use; D005355:Fibrosis / Q000139:chemically induced; D006349:Heart Valve Diseases / Q000139:chemically induced*; D006351:Heart Valves / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D004873:Ergolines; D000077465:Cabergoline